From what 1 stock analysts predict, the share price for Sotera Health Co (SHC) might decrease by 7.01% in the next year. This is based on a 12-month average estimation for SHC. Price targets go from $15.00 to $15.00. The majority of stock analysts believe SHC is a hold. Please note analyst price targets are not guaranteed and could be missed completely.
Sotera Health Co has a total of 1 Wall St Analyst ratings. There are 0 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a hold consensus rating, the expectation is that Sotera Health Co will generate similar returns as the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
david windley Jefferies | Hold | $15.0 | maintained | Dec 10, 2023 |
luke sergott Barclays | Buy | $15.0 | maintained | Nov 1, 2023 |
casey woodring J.P. Morgan | Hold | $15.0 | maintained | Nov 1, 2023 |
sean dodge RBC Capital | Buy | $20.0 | reiterated | Nov 1, 2023 |
patrick b donnelly Citi | Hold | $20.0 | maintained | Aug 28, 2023 |
matthew mishan KeyBanc | Buy | $23.0 | rated | Aug 28, 2023 |
michael polark Wolfe Research | Buy | $21.0 | maintained | Aug 4, 2023 |
tycho peterson J.P. Morgan | Hold | $18.0 | upgraded | Jan 23, 2023 |
amit hazan Goldman Sachs | Hold | $8.0 | maintained | Nov 23, 2022 |
matt miksic Credit Suisse | Buy | $28.0 | maintained | Mar 2, 2022 |
In 2023, SHC generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that SHC's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
SOFI-USD
$8.33
TMUS-USD
$161.76
TXN-USD
$162.4
UPST-USD
$33.9
$27.88
TXG-USD
$49.11